Table 2.
Docetaxel plus lycopene (N = 13) | |
---|---|
PSA Response (≥50% reduction in serum PSA) | |
Events (n) | 10 |
Rate (%) | 76.9 |
95% CI | 46.18–94.96% |
Disease control rate (%) | 92.3 |
95% CI | 63.97–99.8% |
Duration of response (mo) | |
Median | 7.3 |
95% CI | 4.8–13.2 |
Progression free survival (mo) | |
Median | 8 |
95% CI | 5.5–14.7 |
Overall survival (mo) | |
Median | 35.1 |
95% CI | 25.8–57.8 |